Post/November 11, 2026Half of myeloma patients given one CAR-T infusion after an early relapse were progression-free five years onCAR-T at first relapse in myeloma: Legend Biotech says half of 20 early-line CARVYKTI patients stayed progression-free five years after one infusion.HNHealthcare News·November 11, 2026
